The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer

Ki67 is a proliferation marker. It has been proposed as a useful clinical marker for breast cancer subtype classification, prognosis, and prediction of therapeutic response. But the questionable analytical validity of Ki67 prevents its widespread adoption of these measures for treatment decisions in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ailin, Wang, Xiaojing, Fan, Chuifeng, Mao, Xiaoyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597938/
https://www.ncbi.nlm.nih.gov/pubmed/34803903
http://dx.doi.org/10.3389/fendo.2021.687244
_version_ 1784600700439756800
author Zhang, Ailin
Wang, Xiaojing
Fan, Chuifeng
Mao, Xiaoyun
author_facet Zhang, Ailin
Wang, Xiaojing
Fan, Chuifeng
Mao, Xiaoyun
author_sort Zhang, Ailin
collection PubMed
description Ki67 is a proliferation marker. It has been proposed as a useful clinical marker for breast cancer subtype classification, prognosis, and prediction of therapeutic response. But the questionable analytical validity of Ki67 prevents its widespread adoption of these measures for treatment decisions in breast cancer. Currently, Ki67 has been tested as a predictive marker for chemotherapy using clinical and pathological response as endpoints in neoadjuvant endocrine therapy. Ki67 can be used as a predictor to evaluate the recurrence-free survival rate of patients, or its change can be used to predict the preoperative “window of opportunity” in neoadjuvant endocrine therapy. In this review, we will elaborate on the role of Ki67 in neoadjuvant endocrine therapy in breast cancer.
format Online
Article
Text
id pubmed-8597938
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85979382021-11-18 The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer Zhang, Ailin Wang, Xiaojing Fan, Chuifeng Mao, Xiaoyun Front Endocrinol (Lausanne) Endocrinology Ki67 is a proliferation marker. It has been proposed as a useful clinical marker for breast cancer subtype classification, prognosis, and prediction of therapeutic response. But the questionable analytical validity of Ki67 prevents its widespread adoption of these measures for treatment decisions in breast cancer. Currently, Ki67 has been tested as a predictive marker for chemotherapy using clinical and pathological response as endpoints in neoadjuvant endocrine therapy. Ki67 can be used as a predictor to evaluate the recurrence-free survival rate of patients, or its change can be used to predict the preoperative “window of opportunity” in neoadjuvant endocrine therapy. In this review, we will elaborate on the role of Ki67 in neoadjuvant endocrine therapy in breast cancer. Frontiers Media S.A. 2021-11-03 /pmc/articles/PMC8597938/ /pubmed/34803903 http://dx.doi.org/10.3389/fendo.2021.687244 Text en Copyright © 2021 Zhang, Wang, Fan and Mao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Zhang, Ailin
Wang, Xiaojing
Fan, Chuifeng
Mao, Xiaoyun
The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
title The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
title_full The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
title_fullStr The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
title_full_unstemmed The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
title_short The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
title_sort role of ki67 in evaluating neoadjuvant endocrine therapy of hormone receptor-positive breast cancer
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597938/
https://www.ncbi.nlm.nih.gov/pubmed/34803903
http://dx.doi.org/10.3389/fendo.2021.687244
work_keys_str_mv AT zhangailin theroleofki67inevaluatingneoadjuvantendocrinetherapyofhormonereceptorpositivebreastcancer
AT wangxiaojing theroleofki67inevaluatingneoadjuvantendocrinetherapyofhormonereceptorpositivebreastcancer
AT fanchuifeng theroleofki67inevaluatingneoadjuvantendocrinetherapyofhormonereceptorpositivebreastcancer
AT maoxiaoyun theroleofki67inevaluatingneoadjuvantendocrinetherapyofhormonereceptorpositivebreastcancer
AT zhangailin roleofki67inevaluatingneoadjuvantendocrinetherapyofhormonereceptorpositivebreastcancer
AT wangxiaojing roleofki67inevaluatingneoadjuvantendocrinetherapyofhormonereceptorpositivebreastcancer
AT fanchuifeng roleofki67inevaluatingneoadjuvantendocrinetherapyofhormonereceptorpositivebreastcancer
AT maoxiaoyun roleofki67inevaluatingneoadjuvantendocrinetherapyofhormonereceptorpositivebreastcancer

Ejemplares similares